Active substance
Hepatitis a virus inactivated
- Health Canada 4
- UK MHRA 1
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AVAXIM | 02237792 | 160 UNIT / 0.5 ML | SUSPENSION · INTRAMUSCULAR | SANOFI VACCINES CANADA LTD. |
| HAVRIX 1440 | 02187078 | 1440 UNIT / ML | SUSPENSION · INTRAMUSCULAR | GLAXOSMITHKLINE INC |
| HAVRIX 720 JUNIOR | 02231056 | 720 UNIT / 0.5 ML | SUSPENSION · INTRAMUSCULAR | GLAXOSMITHKLINE INC |
| VAQTA | 02229702 | 50 UNIT / ML | SUSPENSION · INTRAMUSCULAR | MERCK CANADA INC |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| AVAXIM SUSPENSION FOR INJECTION IN A PRE-FILLED SYRINGE | PL 23228/0006 | SANOFI WINTHROP INDUSTRIE | POM |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.